GoodRx acquires vitaCare for $150M

GoodRx, a healthcare platform that offers telemedicine and prescription drug discounts, has agreed to acquire vitaCare Prescription Services for $150 million.

GoodRx is acquiring the technology and services platform from TherapeuticsMD, a women’s healthcare company, to continue expanding its pharma manufacturer solutions business. GoodRx’s pharma manufacturer solutions business works with pharmaceutical manufacturers to boost awareness of savings programs among patients and prescribers directly on the its website.

VitaCare aims to make the process of filling prescription drugs simpler and more cost-effective by helping patients navigate key access and adherence barriers for brand medications. VitaCare helps patients understand how they can save and facilitates communications between providers and payors. Patients can also fill prescriptions on the platform through a network of third-party pharmacies.

Like GoodRx, vitaCare’s services aim to help patients fill their prescriptions. Of that 500 million brand prescriptions written every year, only half are filled. Plus, of the filled prescriptions, 29% of patients experienced a delay in receiving their medication due to insurance processes and provider communication delays, according to GoodRx. GoodRx views the acquisition as adding another tool to help patients with access and affordability to their medications in addition to expanding its pharma manufacturer solutions offerings.

“Pharma manufacturers want to help patients find affordable options but too many consumers still face affordability challenges or complex reimbursement processes,” said Doug Hirsch, co-CEO and co-founder of GoodRx. “With vitaCare, we aim to grow our reach and provide new tools for both consumers and providers to help ensure that more patients can access relevant savings programs and navigate prior authorization requirements. We’re excited about the potential to help patients from the point of prescribing through their ongoing refills to ensure they can stay healthy.”

GoodRx has agreed to acquire the company for $150 million in cash, plus $7 million consideration contingent upon vitaCare’s financial performance through 2023. The deal is expected to close mid-2022, subject to customary closing conditions.

Find more healthcare business stories

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.